DXCM
HealthcareDexCom, Inc. · Medical - Devices · $28B
What is DexCom, Inc.?
DexCom, Inc. is a medical device company focused on continuous glucose monitoring (CGM) systems for people living with diabetes. Headquartered in San Diego, California, DexCom markets its products to endocrinologists, physicians, and diabetes educators across the United States and internationally.
DexCom designs, develops, and commercializes CGM systems that allow people with diabetes to track glucose levels in real time — eliminating the need for routine finger-stick testing. The company sells directly to healthcare professionals and generates revenue through device sales and recurring sensor subscriptions. DexCom also partners with third-party digital health developers through its real-time API, extending its platform reach beyond standalone hardware.
DexCom was incorporated in 1999 and is headquartered in San Diego, California.
- DexCom G6 — integrated CGM system for diabetes management
- DexCom G7 — next-generation CGM system with improved form factor
- Dexcom ONE — designed to replace finger-stick glucose testing
- Dexcom Real-Time API — enables third-party digital health integrations
- Dexcom Share — remote glucose monitoring for caregivers and providers
Is DXCM a Good Stock to Buy?
UQS Score rates DXCM as Good overall, reflecting a balanced profile across the five quality pillars.
DexCom's Quality and Growth pillars both register as Good, suggesting the business generates meaningful returns and continues to expand its addressable market. The Risk pillar also comes in at Good, indicating the company's financial structure and operational profile are relatively well-managed compared to sector peers.
The Moat and Valuation pillars both land at Neutral, meaning competitive differentiation and current pricing relative to fundamentals are areas worth watching before committing capital.
See the exact pillar breakdown and full financial metrics by signing up for a UQS Pro account. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does DXCM pay dividends?
No — DexCom, Inc. does not currently pay a dividend.
DexCom does not currently pay a dividend. For a growth-oriented medical device company, this is typical — capital is reinvested into research and development, commercial expansion, and platform partnerships rather than returned to shareholders as income. Investors seeking yield may want to weigh this against the company's reinvestment-driven growth profile.
When does DXCM report earnings?
DexCom reports earnings on a quarterly cadence, consistent with standard practice for US-listed equities.
DexCom's quarterly results tend to reflect trends in CGM adoption, international expansion, and new product launches. Revenue trajectory and guidance updates are closely watched given the company's growth-oriented positioning within the diabetes management market.
For the most recent quarter's results and upcoming reporting dates, visit DexCom's investor relations page directly.
DXCM Price History
-32.2% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in DexCom, Inc.?
Based on DexCom, Inc.'s historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
DXCM Long-term Outlook
DexCom's Good Growth pillar points to continued expansion potential, driven by rising global diabetes prevalence and increasing CGM adoption among both Type 1 and Type 2 patients. The Good Risk profile suggests the company is navigating competitive and operational pressures with reasonable stability. However, the Neutral Valuation pillar indicates the market has already priced in a meaningful portion of the growth story, leaving less room for error if execution falters.
Growth drivers
- Expanding CGM adoption among Type 2 diabetes patients globally
- International market penetration and new country launches
- Third-party digital health integrations via the Dexcom Real-Time API
Key risks
- Intensifying competition in the CGM market from established device makers
- Neutral valuation leaves limited margin of safety if growth slows
- Reimbursement and regulatory changes across international markets
DXCM vs Peers
DexCom operates in the broader medical device landscape alongside companies with different product focuses and business models.
STERIS focuses on sterilization and surgical support services rather than patient-facing monitoring devices, making it a complementary rather than direct competitor in the healthcare device space.
Philips competes across a broad range of health technology segments including imaging and patient monitoring, giving it a wider but less specialized footprint than DexCom's CGM focus.
Zimmer Biomet concentrates on musculoskeletal implants and orthopedic devices, serving a patient population and care setting distinct from DexCom's diabetes management market.
Frequently Asked Questions
What does DexCom do?
DexCom designs and sells continuous glucose monitoring systems that allow people with diabetes to track their blood sugar levels in real time without routine finger-stick testing. The company markets its devices to physicians, endocrinologists, and diabetes educators, and also enables third-party health app developers to integrate its CGM data through an open API.
Does DXCM pay dividends?
DexCom does not pay a dividend. The company reinvests its capital into product development, commercial expansion, and strategic partnerships. Investors focused on income generation should factor this into their assessment of DXCM relative to dividend-paying healthcare peers.
When does DXCM report earnings?
DexCom reports financial results on a quarterly basis, in line with standard US-listed company practice. For exact reporting dates and the most recent results, check DexCom's official investor relations page.
Is DXCM a good stock to buy?
UQS Score rates DXCM as Good overall. The Quality, Growth, and Risk pillars all register positively, while Moat and Valuation are Neutral. Whether DXCM fits your portfolio depends on your risk tolerance and investment horizon. The full pillar breakdown is available to UQS Pro members.
Is DXCM overvalued?
DXCM's Valuation pillar is rated Neutral, suggesting the stock is neither clearly cheap nor obviously expensive relative to its fundamentals. The market appears to have priced in a significant portion of the company's growth expectations. Pro members can view the complete valuation metrics behind this rating.
How does DXCM compare to its competitors?
DexCom occupies a specialized niche in continuous glucose monitoring, while peers like Philips and STERIS operate across broader healthcare device and services segments. DexCom's focused product portfolio in diabetes management differentiates it from more diversified medical device companies. See the competitor comparison section above for more context.
What is DXCM's market cap bracket?
DexCom is classified as a large-cap company, placing it among the more established and widely followed names in the medical device sector. Large-cap status generally reflects meaningful revenue scale and institutional investor coverage.
Who founded DexCom?
DexCom was founded by John F. Burd and others, with the company incorporated in 1999 and headquartered in San Diego, California. Full founding history is publicly available through DexCom's corporate and investor relations materials.
Is DXCM a long-term quality indicator?
From a quality-scoring perspective, DXCM's Good ratings across Quality, Growth, and Risk pillars suggest a business with durable characteristics worth monitoring over a longer horizon. The Neutral Moat rating is a consideration — sustainable competitive advantage is a key factor in long-term quality assessments. Pro members can explore the full breakdown.
What is the main competitive advantage of DexCom?
DexCom's primary competitive advantage lies in its specialized focus on CGM technology, its established relationships with diabetes care providers, and its ecosystem of third-party integrations through the Dexcom Real-Time API. However, the UQS Moat pillar rates this advantage as Neutral, reflecting ongoing competitive pressure in the CGM market.
What sector does DXCM belong to?
DexCom is classified in the Healthcare sector, specifically within the medical devices industry. It focuses on diabetes management technology, a segment experiencing growing demand as global diabetes prevalence rises and CGM adoption expands beyond Type 1 into the broader Type 2 patient population.
Is DXCM a growth stock or value stock?
Based on its UQS pillar profile, DXCM leans toward the growth side — the Growth pillar is rated Good, reflecting meaningful expansion potential. The Valuation pillar is Neutral, suggesting the stock is not priced as a deep-value opportunity. It may appeal more to growth-oriented investors than those seeking undervalued assets.
Unlock Full DXCM Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the exact score for all five UQS pillars
- ✓Access complete financial metrics and trend data
- ✓Compare DXCM against sector peers side by side
- ✓Screen for stocks with similar quality profiles
- ✓Get the full analyst-style breakdown in one place
Pro Analysis
DXCM — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 22, 2026 | 68.8 | 84.0 | 50.0 | 76.1 | 78.7 | 54.9 | 0.0 |
| May 21, 2026 | 68.8 | 84.2 | 50.0 | 76.1 | 78.7 | 55.1 | -1.5 |
| May 17, 2026 | 70.3 | 85.9 | 50.0 | 76.4 | 78.7 | 61.5 | -0.5 |
| May 14, 2026 | 70.8 | 86.5 | 50.0 | 76.5 | 78.7 | 63.5 | +0.4 |
| May 12, 2026 | 70.4 | 86.4 | 50.0 | 76.5 | 78.7 | 61.3 | +1.9 |
| May 10, 2026 | 68.5 | 83.3 | 50.0 | 76.5 | 78.7 | 53.9 | -2.2 |
| May 8, 2026 | 70.7 | 86.0 | 50.0 | 76.5 | 78.7 | 63.9 | +2.3 |
| May 4, 2026 | 68.4 | 79.7 | 50.0 | 76.5 | 76.2 | 61.9 | -0.1 |
| May 3, 2026 | 68.5 | 79.7 | 50.0 | 76.8 | 76.2 | 61.7 | +0.1 |
| May 1, 2026 | 68.4 | 79.7 | 50.0 | 76.8 | 76.2 | 61.6 | +0.3 |
DXCM — Pillar Breakdown
Quality
— 84.1/100 (25%)DexCom, Inc. demonstrates outstanding capital efficiency and profitability, placing it among the highest-quality businesses in the market.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Asset productivity — how much gross profit each dollar of assets generates.
Free cash flow relative to market value.
Growth
— 76.1/100 (20%)DexCom, Inc. is growing rapidly with strong revenue and earnings expansion.
Revenue trajectory over the last twelve months.
Compound annual revenue growth rate over 3 years.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Analyst consensus for future earnings growth.
Risk
— 78.7/100 (15%)DexCom, Inc. carries minimal financial risk with conservative leverage and strong solvency.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 54.9/100 (15%)DexCom, Inc. has a mixed valuation — some metrics suggest fair value while others appear stretched.
Inverse of forward P/E — higher yield means cheaper stock.
How many years of FCF the market cap represents.
P/E relative to earnings growth — lower is more attractive.
Enterprise value multiple relative to sector median.
Moat
— 50/100 (25%)DexCom, Inc. possesses some competitive advantages but faces meaningful competition. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for DXCM.
Score Composition
Financial Data
More Stock Analysis
How is the DXCM UQS Score Calculated?
The UQS (Unified Quality Score) for DexCom, Inc. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses DexCom, Inc.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether DexCom, Inc. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.